Patent: 6,486,204
✉ Email this page to a colleague
Summary for Patent: 6,486,204
Title: | Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug |
Abstract: | A COX-2 selective inhibiting drug is disclosed as useful in treating or preventing prostate cancer. The compound is used alone or in combination with other drugs. |
Inventor(s): | Waldstreicher; Joanne (Scotch Plains, NJ), Morrison; Briggs W. (Watchung, NJ) |
Assignee: | Merck & Co., Inc. (Rahway, NJ) |
Application Number: | 09/771,315 |
Patent Claims: | see list of patent claims |
Details for Patent 6,486,204
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2020-01-28 |
Clinigen, Inc. | PROLEUKIN | aldesleukin | For Injection | 103293 | 05/05/1992 | ⤷ Try a Trial | 2020-01-28 |
Servier Pharmaceuticals Llc | ONCASPAR | pegaspargase | Injection | 103411 | 02/01/1994 | ⤷ Try a Trial | 2020-01-28 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2020-01-28 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2020-01-28 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2020-01-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |